Brief: Moonlake Immunotherapeutics Announces Positive Outcome From Type B Meeting With U.S. FDA
08/01/2026 13:26
Jan 8 (Reuters) - MoonLake Immunotherapeutics MLTX.O: MOONLAKE IMMUNOTHERAPEUTICS ANNOUNCES POSITIVE OUTCOME FROM TYPE B MEETING WITH U.S. FDA AND ANNOUNCES INVESTOR DAY MOONLAKE IMMUNOTHERAPEUTICS - FDA CONFIRMS MOONLAKE CAN ESTABLISH SEE WITHOUT ADDITIONAL TRIALS MOONLAKE IMMUNOTHERAPEUTICS - PLANS BLA SUBMISSION FOR SLK IN HS IN H2 2026 Source text: ID:nGNX5r5G75 Further company coverage: MLTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on MoonLake Immunotherapeutics
See all newsMoonLake jumps as AbbVie's weak skin drug data eases competition fears
Brief: Moonlake Immunotherapeutics Files For Mixed Shelf Offering, Size Not Disclosed
MoonLake Immunotherapeutics reports results for the quarter ended June 30 - Earnings Summary
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial (updated)
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial